Prepared by 503A drug stores (patient-specific) or 503B outsourcing centers (mass, under FDA oversight) from mass substances that are FDA-approved, lug a USP monograph, or sit in Group 1 of the 503A bulks checklist. BPC-157, TB-500, CJC-1295, ipamorelin, and thymosin alpha-1 moved into Classification 1 under analysis in April 2026 and are pending the July
